Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep Sells 9,200 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $20.42, for a total value of $187,864.00. Following the transaction, the chief financial officer owned 145,355 shares of the company’s stock, valued at $2,968,149.10. This represents a 5.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ivan Hyep also recently made the following trade(s):

• On Tuesday, April 21st, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The stock was sold at an average price of $23.00, for a total value of $211,600.00.
• On Monday, March 23rd, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.52, for a total value of $170,384.00.
• On Wednesday, March 4th, Ivan Hyep sold 2,963 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.25, for a total value of $54,074.75.
• On Tuesday, March 3rd, Ivan Hyep sold 13,555 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.22, for a total value of $246,972.10.

Bicara Therapeutics Price Performance

Shares of Bicara Therapeutics stock opened at $21.98 on Wednesday. Bicara Therapeutics Inc. has a 1 year low of $8.48 and a 1 year high of $24.25. The company has a market capitalization of $1.44 billion, a P/E ratio of -7.91 and a beta of -0.57. The business has a 50 day moving average price of $21.23 and a 200 day moving average price of $18.45.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.21). As a group, research analysts expect that Bicara Therapeutics Inc. will post -3.37 EPS for the current fiscal year.

Institutional Trading of Bicara Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC grew its stake in shares of Bicara Therapeutics by 26.2% during the 1st quarter. Janus Henderson Group PLC now owns 3,339,218 shares of the company’s stock valued at $66,350,000 after buying an additional 692,933 shares during the period. Rock Springs Capital Management LP grew its stake in shares of Bicara Therapeutics by 14.0% during the 1st quarter. Rock Springs Capital Management LP now owns 489,095 shares of the company’s stock valued at $9,728,000 after buying an additional 60,000 shares during the period. Quantinno Capital Management LP grew its stake in shares of Bicara Therapeutics by 16.1% during the 1st quarter. Quantinno Capital Management LP now owns 17,612 shares of the company’s stock valued at $350,000 after buying an additional 2,447 shares during the period. Orbimed Advisors LLC grew its stake in shares of Bicara Therapeutics by 219.1% during the 1st quarter. Orbimed Advisors LLC now owns 667,300 shares of the company’s stock valued at $13,273,000 after buying an additional 458,200 shares during the period. Finally, Siren L.L.C. grew its stake in shares of Bicara Therapeutics by 11.2% during the 1st quarter. Siren L.L.C. now owns 5,802,970 shares of the company’s stock valued at $115,421,000 after buying an additional 586,001 shares during the period.

Analyst Upgrades and Downgrades

BCAX has been the subject of several analyst reports. Wells Fargo & Company boosted their price target on Bicara Therapeutics from $11.00 to $16.00 and gave the company an “equal weight” rating in a report on Tuesday, March 31st. The Goldman Sachs Group boosted their price target on Bicara Therapeutics from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Tuesday, May 12th. Morgan Stanley boosted their price target on Bicara Therapeutics from $36.00 to $37.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Citigroup initiated coverage on Bicara Therapeutics in a report on Thursday, January 29th. They issued an “outperform” rating for the company. Finally, HC Wainwright boosted their price target on Bicara Therapeutics from $40.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Bicara Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.27.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.